From the Director

Welcome to Tufts CSDD's third Quarterly Update of 2014, providing an overview of current CSDD research, recent publications, staff presentations, and other news.

I'm very excited to announce that in November we will release the results of our newest study on the cost of drug development. Like past CSDD studies, our new study is a comprehensive and scholarly assessment of drug development costs based on data provided by a mix of drug and biopharmaceutical companies. As always, lead author, Joseph DiMasi, and co-authors Henry Grabowski and Ron Hansen, made sure that the study is scientifically airtight, to buffer it from the deluge of attacks we typically receive from critics of the study. On the other hand, we know that the number we report will quickly be embraced by policy-makers, regulators, academics, and industry as the "true" cost of drug development. Stay tuned for the date and further details about this important event.

In other news, I'm proud to announce the academic promotions of several of CSDD's faculty. Director of Research Dr. Christopher Milne, Director of Economic Analysis Dr. Joseph DiMasi, and Dr. Joshua Cohen have all been promoted to the rank of Research Associate Professor at Tufts University School of Medicine. It is well-deserved recognition of their scholarly achievements as well as their worldwide reputation for academic excellence in the fields of law, economics, and health policy. Congratulations to my three esteemed colleagues!

As always, feel free to contact me directly to share your thoughts and perspectives. And thank you for your support.

 

Sincerely, 
 
Kenneth I Kaitin, PhD
Professor and Director

Research Opportunities 

• Benchmarking Global Clinical Supply Logistics Practices and Performance
• Benchmarking Study Volunteer Screen Failure, Enrollment and Drop-out Rates by Therapeutic Area and Phase
• Evaluating the Impact of Integrated Outsourcing Relationships on Performance and Quality
• Measuring the Adoption of eClinical Solutions and Standards

Cohen JP. Patient access to orphan drugs faces new set of challenges. Formulary. [Published online before print September 15, 2014]

Cohen JP, Felix AE, Riggs K, Gupta A. Barriers to market uptake of biosimilars in the US. Generics and Biosimilars Initiative. 2014;3(3):107-114.

SEPTEMBER

Kenneth Kaitin & Kenneth Getz: Optimizing Drug Development Performance, Boston, MA, September 15-16

OCTOBER

Kenneth Getz: Outsourcing East, Boston, MA, October 7-8

NOVEMBER

Kenneth Kaitin: Fudan University's Center for the Study of Pharmaceutical and Healthcare Strategy Symposium, Shanghai, China, November 4

Kenneth Getz: CDISC Interchange, Bethesda, MD, November 12-13